- Open Access
Thymosin β4 coated nanofiber scaffolds for the repair of damaged cardiac tissue
© Kumar et al.; licensee BioMed Central Ltd. 2014
- Received: 22 January 2014
- Accepted: 4 March 2014
- Published: 24 March 2014
After a cardiac event, proper treatment and care of the damaged tissue is crucial in restoring optimal cardiac function and preventing future cardiac events. Recently, thymosin β4 has been found to play a vital role in cardiac cell health and development by regulating angiogenesis, inflammatory responses, and wound healing. We proposed that defined poly(ϵ-caprolactone) (PCL) nanoscaffolds coated with thymosin β4 could efficiently differentiate murine-derived cardiomyocytes into functioning cardiac tissue. PCL nanoscaffolds were developed through electrospinning technology, and subsequently coated with a thymosin β4 solution. Cardiomyocytes were seeded on coated and uncoated nanoscaffolds and observed for six days via fluorescent and electron microscopy. Our results demonstrated a robust growth and differentiation of cardiomyocytes on coated nanoscaffolds compared with uncoated, showing potential for nanoscaffold-mediated cardiac cell replacement in vivo after an MI or other cardiac event.
Cardiac cell health post-myocardial infarction is imperative in the proper future functioning of the heart [1, 2]. After MI, formation of fibrotic scar issue impairs the ability of the heart to properly function, leading to higher risk for a second cardiac event [3, 4]. Developing new methods to treat these disease events is imperative. Literature has shown that the 43-amino acid protein thymosin β4 (Tβ4) acts by sequestering G-actin monomers, subsequently effecting actin-cytoskeletal organization necessary for cardiac cell motility, organogenesis, and other crucial cellular events necessary for repair .
The correlation between Tβ4 and cardiac cells has been of great interest and debate worldwide , but the overwhelming majority of studies have pointed to Tβ4 having a positive effect. Using epicardium derived progenitor cells (EPDCs), Gajzer et al.  and Smart, et al.  have shown in vivo that EPDCs primed with Tβ4 differentiate into cardiomyocytes, and can be used to repair the myocardium after ischemic damage. Downregulation of Tβ4 using a blocking antibody was shown to decrease survival of EPDC-derived cardiomyocytes, and this affect could be reversed by exogenous addition of Tβ4 . It has been widely demonstrated that Tβ4 can promote cardiac cell migration [5, 10, 11], activate proliferation of cardiac fibroblasts and endothelial cells [5, 7–9, 12], and promote neoangiogenesis (development and formation of blood vessels) [5, 10, 11, 13]. It has also been shown in rodent and pig models of myocardial infarctions that Tβ4 has potent effects in limiting the amount of damage caused by coronary ligation and, more recently, Tβ4 administration before injury appeared to prime a population of epicardium-derived progenitor cells to become new cardiomyocytes .
Besides the use of Tβ4, there have been various techniques employed to regrow and differentiate cardiomyocytes (for a comprehensive review of the methodology, see Ref.  and ). Our focus will be on the applications of a polymer-based nanofiber scaffold to be used as a platform for animal cell growth and differentiation. For biomedical applications these nanoscaffolds are made of naturally occurring, biocompatible materials such as collagen, starch, poly(L-lactide) and poly(ϵ-caprolactone) (PCL), or any combination thereof  that will slowly and consistently dissolve in vivo. This dissolving can be used to deliver such things as therapeutic drugs  or bioactive molecules . PCL fibers can be produced by various methods, including phase-separation, self-assembly, or electrospinning , each having benefits and detriments depending on the application.
Here, we aimed to use the beneficial properties of PCL to develop a scaffold for the growth and differentiation of cardiomyocytes derived from rat cardiac tissue. The goal was to develop a structurally sound scaffold coated with Tβ4 that would successfully propagate cells ex vivo for future in vivo cardiac tissue repair applications.
PCL solution formulation
PCL tablets were purchased from Sigma Aldrich (CAS 24980; St. Louis, MO). Dichloromethane (DCM) and N,N-dimethylformamide (DMF) were purchased from Acros Organics (Geel, Belgium). PCL tablets weighing 1.5 g were dissolved in a solvent mixture containing a 1:4 ratio of DCM to DMF. This combination was sonicated for 1 hour to ensure tablets were fully dissolved.
Electrospinning of nanoscaffold
1.5 mL PCL/DMF/DCM solution was suctioned into a syringe and attached to a flow rate controller (Thermo Scientific, Waltham, MA). The solution was pumped at a flow rate of 0.5 mL/h. A Voltmeter lead was attached to the syringe needle and the other lead was attached to a rolling drum that housed an aluminum sheet (Oriental Motor, Tokyo, Japan). The rolling drum was mounted on an E7 Limo easy linear motion controller (Oriental Motor) for linear and rotational fiber distribution. The Human Machine Interface (Omron, Kyoto, Japan) was set at a 3 hr run time, a starting position of the E7 Limo at 105 mm, and a rolling drum speed of 630RPM. A potential of 12 kV was applied between the spinneret and grounded collector located 12 cm below the spinneret to pull the solution from the syringe and accurately line the fibers to the rolling drum mounted on the E7 Limo.
IR nanoscaffold characterization
A Nicolet iS5 spectrometer with an iD1 Transmission adapter (Thermo Scientific, Waltham, MA) was used to perform Fourier transformed infrared spectroscopy (FTIR). The fibers were measured to determine characteristic peaks relating to bond stretching and rocking, using air as a blank. The FTIR analysis was carried out over a wave number range between 4000 and 400 cm-1 at a resolution of 2 cm-1.
Microscopic nanoscaffold characterization
Scanning electron microscopy (SEM) was performed to visualize the initial fibers. Fibers were mounted on aluminum mount-M4 sample holders (Electron Microscopy Sciences, Hatfield, PA) and placed in a Denton Bench Top Turbo III vaccum chamber (Denton Vacuum, Moorestown, NJ) for coating with a 50:50 mix Au:Pd to aid visualization. The samples were placed into the SEM (Hitachi S4700, Hitachi High Technologies, Tokyo, Japan) and images were taken from 1000× to 5000× to ensure linearity and even size.
Transmission electron microscopy was performed on Day 4 of treated cell culture to ensure even cell distribution and proliferation through the fiber scaffold. Cell and fiber suspensions were cryogenically prepared and mounted into the Libra 120 Transmission Electron Microscope (Carl Zeiss, Inc., Thornwood, NY).
An EvosFL Cell Imaging System (Life Technologies, Carlsbad, CA) was used to monitor cell growth and determine cell counts. Cells were washed and placed on the microscope stage. An image was taken, and the Toolbar function was used to place a hemocyometer grid on the screen for cell counts.
Nanofiber scaffolds were transferred into petri dishes, sterilized with 70% ethanol for several hours, rinsed with phosphate buffered saline (PBS), and coated with 0.1% polylysine aqueous solution for 4 to 6 h prior to cell seeding. Treated scaffolds were coated with thymosin β4 solutions at concentrations of 0.5-7.5% w/v. Prior to seeding but following coating, scaffolds were rinsed with Ultrapure water (Millipore) to remove any excess thymosin β4 residue not sticking to the scaffold.
Cells were extracted as described in , in which collagenase digestion of murine left ventricles was followed by centrifugal separation. Cultures were prepared in Cardiomyocyte Differentiation Medium (StemCell Technologies) and seeded on two scaffolds: One on a nanofiber scaffold treated with a thymosin β4 coating; the other was prepared on an uncoated scaffold for comparison. Stem cells were seeded at a concentration of 1×106 over both scaffolds and allowed to grow in a cultured medium. Cells were incubated in a Forma Steri-Cycle CO2 Incubator (Thermo Scientific, Waltham, MA) at 36.5°C and 3.0% CO2. Cardiomyocytes were characterized based on control and antibody staining as described in the Cardiomyocyte Characterization Kit protocol (Millipore).
The statistical significance of the results was determined using analysis of variance (ANOVA) and a multiple means comparison function (t-test) in JMP with an alpha level of 0.05. All error bars are reported in mean ± standard error from the mean, with n = 5 unless otherwise noted.
Coating of nanofiber
Cell propagation on coated nanoscaffolds
Our work was performed with the goal of determining the effect of a new and novel coating on a nanoscaffold to be used in repairing cardiac muscle after damaging cardiovascular events. After fabrication any nanoscaffold construct can be subjected to coating, allowing the fiber to display novel researcher-selected properties such as hydrophobicity, bioactivity, or fluorescence . The bioactive coatings can significantly enhance cell growth, cell signaling, and in vivo biocompatibility .
Based on previous literature findings, thymosin β4 was chosen as a coating for the scaffolds to propagate and differentiate cardiomyocytes derived from mice to develop an ex vivo growth system. To our knowledge, this is the first time PCL nanofiber scaffolds were coated with a thymosin β4 solution and used for successful growth and preparation of cardiomyocytes in an ex vivo system. The optimal concentration levels of 1–1.5% Tβ4 coating presumably allowed a positive combinatorial effect with the PCL electrospun nanoscaffolds. This effect was stunted with an overwhelming proportion of Tβ4 greater than 2% (data not shown), and is comparable to previously described in vitro data where an overwhelming proportion of Tβ4 caused uncontrolled disassociations of actin bundles . We therefore propose the use of lower and therefore less costly concentrations of Tβ4 could be efficiently used for cell differentiation.
Poly(ϵ-caprolactone) (PCL) has advantageous chemical properties that lends itself to biological applications. PCL is a biodegradable polymer with a slow rate of degradation  and low toxicity . It also shows high anisotropy in cardiomyocyte cell culture when produced through electrospinning methods, and, despite being a soft and flexible material PCL fibers are able to withstand the contraction force of a beating heart . PCL nanofiber scaffolds provided a sturdy platform for ex vivo cell growth and are a strong, biocompatible, and flexible delivery system of cells to an in vivo system.
Throughout this study five replicate PCL fiber solutions electrospun for three hours on to tin foil-coated rolling drums were analyzed using multiple microscopic techniques to ensure the desired topographical features of linearity and porosity were achieved. Electrospinning allows nanoscaffolds produced to have extremely small diameters, creating a high surface area to volume ratio on which the cells can attach and proliferate . Electrospun fibers also have topographical features that encourage cell adhesion, growth, and differentiation . Our early microscopic analysis was performed to insure the nanoscaffolds were linear enough to encourage cell growth. Increased linearity is advantageous because nanoscaffolds with linear fibers are able to better differentiate cells and have been used to induce polarity of susceptible cell lines when compared to more loosely based scaffold systems [24, 25].
The cryo-TEM, was performed to measure whether the cells were properly integrating into the nanoscaffold meshwork. Electrospinning produces fibers with a high porosity and interconnected pore structure, a crucial property that allows cells and nutrients to migrate from the exterior to the interior of the fibers . We chose to perform the cryo-TEM as a self-check because, from our expectations and comparing the growth slope from Day 2 to Day 4, the significance between Day 4 coated and non-coated was not as large as expected. We surmised this was due to the increase in average number of cells on the uncoated nanoscaffold on Day 4, which was not significantly different from the previous uncoated control on Day 2 but nonetheless slightly skewed the results (Figure 5a&c). More replications or an increase in initial cell seeding would presumably have shown a significant increase between these two days.
Many biocompatible nanoscaffolds have been used for in vitro and in vivo repair of various muscle and connective tissues. Here, we developed a PCL nanoscaffold for use in repair of cardiac muscle. As cardiovascular issues are the number one killer in the world, the future for this application is tremendous. Further in vivo studies will be needed to replicate literature values on the strength of PCL in the heart, and to insure thymosin β4 can prove to be continually successful.
The results obtained in this study suggest that thymosin β4 is a cardiomyocyte growth factor that, when present, significantly increases cell growth and proliferation. A biocompatible and biodegradable nanoscaffold was successfully created from a PCL polymer and coated with an active concentration of Tβ4. This nanoscaffold provided a support system by which murine-derived cardiomyocytes were successfully differentiated into functioning and thriving cardiac tissue. While the regenerative effects of Tβ4 have been well documented, to our knowledge this is the first time a platform for Tβ4 utilization had been fully developed and tested. This successful differentiation of murine-derived cardiomyocytes treated with Tβ4 on nanofiber scaffolds may serve as a simple and effective solution to repair various impairments of damaged cardiac tissue through in vivo implantation.
Dr. Kumar would like to acknowledge the UDRF (University of Delaware Research Foundation) Award he received from the University of Delaware. We would also like to thank Dr. Dula Man from Delaware State University for providing us the opportunity to develop the nanoscaffolds.
- Xu J, Carratero OA, Zhu L, Shesely EG, Rhaleb N-E, Dai X, Wang L, Yang JJ, Yang X-P: Protective role of AT2 and B1 receptors in kinin B2-receptor-knockout mice with myocardial infarction. Clin Sci (Lond). 2013, 124: 87-96. 10.1042/CS20120341.View ArticleGoogle Scholar
- Sinner MF, Greiner MA, Mi X, Hernandez AF, Jensen PN, Piccini JP, Setoguchi S, Walkey AJ, Heckbert SR, Benjamin EJ, Curtis LH: Completion of guideline-recommended initial evaluation of atrial fibrillation. Clin Cardio. 2012, 35: 585-593. 10.1002/clc.22055.View ArticleGoogle Scholar
- Protti A, Dong X, Sirker A, Botnar R, Shah AM: MRI-based prediction of adverse cardiac remodeling after murine myocardial infarction. Am J Physiol Heart Circ Physiol. 2012, 303: H309-H314. 10.1152/ajpheart.00208.2012.View ArticleGoogle Scholar
- Dong H, Mosca H, Gao E, Akins RE, Gidding SS, Tsuda T: Integrated wall stress: a new methodological approach to assess ventricular workload and myocardial contractile reserve. J Transl Med. 2013, 11: 183-10.1186/1479-5876-11-183.View ArticleGoogle Scholar
- Marquette IB, Saxena A, White MD, DiMalo JM, Srivastava D: Thymosin B4 activates intergrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004, 432: 466-472. 10.1038/nature03000.View ArticleGoogle Scholar
- Segers VFM, Lee RT: Stem-cell therapy for cardiac disease. Nature. 2008, 451: 937-942. 10.1038/nature06800.View ArticleGoogle Scholar
- Yoshimoto H, Shin YM, Teraia H, Vacanti JP: A biodegradable nanofiber scaffold by electrospinning and its potential for bone tissue engineering. Biomaterials. 2003, 24: 2077-2082. 10.1016/S0142-9612(02)00635-X.View ArticleGoogle Scholar
- Gajzer DC, Balbin J, Chaudhry HW: Thymosin β4 and cardiac regeneration: are we missing a beat?. Stem Cell Rev. 2012, 9: 303-312.View ArticleGoogle Scholar
- Smart N, Bollini S, Dubé KN, Vieira JM, Zhou B, Riegler J, Price AN, Lythgoe MF, Davidson S, Yellon D, Pu WT, Riley PR: Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart. Ann N Y Acad Sci. 2012, 1269: 92-101. 10.1111/j.1749-6632.2012.06708.x.View ArticleGoogle Scholar
- Hinkel R, El-Aouni C, Olson T, Horstkotte J, Mayer S, Müller S, Willhauck M, Spitzweg C, Gildehaus FJ, Münzing W, Hannappel E, Bock-Marquette I, DiMaio JM, Hatzopoulos AK, Boekstegers P, Kupatt C: Thymosin β4 is an essential paracrine factor of embryonic endothelial progenitor cell–mediated cardioprotection. Circulation. 2008, 117: 2232-2240. 10.1161/CIRCULATIONAHA.107.758904.View ArticleGoogle Scholar
- Zhoua B, Honor LB, Ma Q, Oh JH, Lin RZ, Melero-Martin JM, Von Gise A, Zhou P, Hu T, He L, Wu KH, Zhang H, Zhang Y, Pu WT: Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J Mol Cell Cardiol. 2012, 52: 43-47. 10.1016/j.yjmcc.2011.08.020.View ArticleGoogle Scholar
- Srivastava D, Ieda M, Fu J, Qian L: Cardiac repair with thymosin β4 and cardiac reprogramming factors. Ann N Y Acad Sci. 2012, 1270: 66-72. 10.1111/j.1749-6632.2012.06696.x.View ArticleGoogle Scholar
- Kraehenbuehla TP, Ferreirac LS, Zammaretti P, Hubbell JA, Langer R: Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials. 2009, 30: 4318-4324. 10.1016/j.biomaterials.2009.04.057.View ArticleGoogle Scholar
- Kawaguchi N, Hatta K, Nakanishi T: 3D-Culture system for heart regeneration and cardiac medicine. BioMed Research International. 2013, doi:10.1155/2013/895967Google Scholar
- Doll TAPF, Raman S, Dey R, Burkhard P: Nanoscale assemblies and their biomedical applications. J R Soc Interface. 2013, 10: doi:10.1098/rsif.2012.0740Google Scholar
- Prabu P, Kim KW: Antimicrobial drug release scaffolds of natural and synthetic biodegradable polymers. Macromol Res. 2008, 16: 303-307. 10.1007/BF03218521.View ArticleGoogle Scholar
- Liu T, Xu J, Chan BP, Chew SY: Sustained release of neurotrophin-3 and chondroitinase ABC from electrospun collagen nanofiber scaffold for spinal cord injury repair. J Biomed Mater Res Part A. 2011, 100: 236-242.Google Scholar
- Çapkın M, Cakmak S, Kurt FO, Gumusderelioglu M, Sen BH, Türk BT, Deliloglu-Gurhan Sİ: Random/aligned electrospun PCL/PCL-collagen nanofibrous membranes: comparison of neural differentiation of rat AdMSCs and BMSCs. Biomed Mater. 2012, 7: 045013-10.1088/1748-6041/7/4/045013. doi:10.1088/1748-6041/7/4/045013View ArticleGoogle Scholar
- Sanger JM: Increasing intracellular concentrations of thymosin beta 4 in PtK2 cells: effects on stress fibers, cytokinesis, and cell spreading. Cell Motil Cytoskeleton. 1995, 31: 307-322. 10.1002/cm.970310407.View ArticleGoogle Scholar
- Kai D, Prabhakaran MP, Jin G, Ramakrishna S: Guided orientation of cardiomyocytes on electrospun aligned nanofibers for cardiac tissue engineering. J Biomed Mater Res. 2011, 98: 379-386.View ArticleGoogle Scholar
- Yeo M, Lee H, Kim G: Three-dimensional hierarchical composite scaffolds consisting of polycaprolactone, β-tricalcium phosphate, and collagen nanofibers: fabrication, physical properties, and in vitro cell activity for bone tissue regeneration. Biomacromolecules. 2011, 12: 502-510. 10.1021/bm1013052.View ArticleGoogle Scholar
- Bakhshandeh B, Soleimani M, Ghaemi N, Shabani I: Effective combination of aligned nanocomposite nanofibers and human unrestricted somatic stem cells for bone tissue engineering. Acta Pharmacol Sin. 2011, 32: 626-636. 10.1038/aps.2011.8.View ArticleGoogle Scholar
- Gupta D, Venugopal J, Prabhakaran MP, Dev VRG, Low S, Choon AT, Ramakrishna S: Aligned and random nanofibrous substrate for the in vitro culture of Schwann cells for neural tissue engineering. Acta Biomater. 2009, 5: 2560-2569. 10.1016/j.actbio.2009.01.039.View ArticleGoogle Scholar
- Bakera BM, Shah RP, Silverstein AM, Esterhai JL, Burdick JA, Mauck RL: Sacrificial nanofibrous composites provide instruction without impediment and enable functional tissue formation. Proc Natl Acad Sci. 2012, doi:10.1073/pnas.1206962109Google Scholar
- Louch WE, Sheehan KA, Wolska BM: Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol. 2011, 51: 288-298. 10.1016/j.yjmcc.2011.06.012.View ArticleGoogle Scholar
- Vasita R, Katti DS: Nanofibers and their applications in tissue engineering. Int J Nanomedicine. 2006, 1: 15-30. 10.2147/nano.2006.1.1.15.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.